I feel like we need another hour to go into more of these details, but for the sake of brevity and our listeners out there, I have one last question
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
This visit includes a full provider evaluation, InBody body composition scan, symptom review, and protocol design
Therefore, we would suggest that GLP-1 receptor agonists may help slow the progression of AD
It influences your whole body and mind, making it hard to stay active and healthy enough to develop muscle
At the same time, pharmaceutical companies have faced increasing public and regulatory pressure to lower self-pay (cash) prices for these medications though pricing and discount programs vary by drug and pharmacy
